Fosamax vs Evenity (Romosozumab): Titration Speed and Tolerability Compared

How Each Drug Works and Why Titration Differs

Alendronate suppresses osteoclast-mediated bone resorption by binding to hydroxyapatite and blocking farnesyl pyrophosphate synthase. Romosozumab inhibits sclerostin, simultaneously increasing bone formation and decreasing resorption. That dual mechanism explains why romosozumab achieves BMD gains in months that would take alendronate years. Neither drug requires dose titration in the traditional sense, but they differ sharply in duration and sequencing requirements.

Alendronate Dosing: Fixed and Indefinite

Alendronate starts at 70 mg once weekly from day one. There is no ramp-up period and no dose escalation. Patients with a creatinine clearance below 35 mL/min should avoid bisphosphonates entirely per FDA labeling, but within the approved population the dose stays constant [1]. Long-term use beyond 5 years carries a small risk of atypical femoral fracture, which is why many clinicians reassess need after 3 to 5 years. The American College of Rheumatology notes that a drug holiday of 1 to 2 years may be appropriate for lower-risk patients after 5 years of bisphosphonate therapy [2].

Romosozumab Dosing: Fixed Dose, Strict Time Limit

Romosozumab is administered as two 105 mg subcutaneous injections (total 210 mg) once monthly for 12 months. The 12-month cap is not a titration endpoint, it is a regulatory and pharmacological boundary. The anabolic window closes after approximately one year of sclerostin inhibition, and BMD gains will reverse without subsequent antiresorptive therapy [3]. Transitioning to alendronate, zoledronic acid, or denosumab immediately after month 12 is mandatory to consolidate gains.

Why "Titration Speed" Means Something Different Here

For conventional drugs like SSRIs or antihypertensives, titration means gradually increasing a dose over weeks to balance efficacy and tolerability. Neither alendronate nor romosozumab follows that model. Alendronate's tolerability issue is primarily GI-related and emerges quickly, so the clinical team learns within the first 4 to 8 weeks whether the drug is well tolerated [4]. Romosozumab's tolerability concerns center on injection-site reactions and cardiovascular events that may surface within the 12-month treatment window, not from dose escalation.

Fracture Efficacy: What the Trials Actually Show

FIT Trial (Alendronate)

The Fracture Intervention Trial (FIT, N=2,027 women with low femoral neck BMD) showed alendronate reduced vertebral fracture risk by 47% over 3 years compared with placebo (relative risk 0.53, 95% CI 0.41 to 0.68) [5]. Hip fracture risk fell by 51% in women with prevalent vertebral fractures at baseline. These data, published in JAMA in 1998, remain the foundation of alendronate's clinical positioning [5].

ARCH Trial (Romosozumab Then Alendronate)

The ARCH trial (N=4,093 postmenopausal women with osteoporosis and high fracture risk) compared 12 months of romosozumab followed by alendronate against alendronate alone for 24 months [6]. The romosozumab-then-alendronate sequence reduced new vertebral fracture risk by 48% relative to alendronate alone (P<0.001) and reduced clinical fracture risk by 27% (hazard ratio 0.73, 95% CI 0.61 to 0.87, P<0.001) [6]. Hip fracture risk was reduced by 38% (P=0.02) [6].

BMD Gains: A Quantitative Gap

At 12 months in the ARCH trial, romosozumab produced a lumbar spine BMD increase of 13.3% versus 5.4% with alendronate alone [6]. At the total hip, romosozumab gained 6.9% versus 2.9% with alendronate [6]. These differences are clinically meaningful because a 1-standard-deviation improvement in BMD T-score corresponds to roughly a 50% reduction in fracture risk based on epidemiological modeling [7].

Tolerability Profiles: A Side-by-Side Look

Tolerability shapes real-world adherence more than any pharmacokinetic property. Both drugs carry important safety signals, but they affect different organ systems and appear at different timepoints.

Alendronate Tolerability

Upper GI adverse effects affect 10 to 30% of patients in the first weeks of therapy [4]. Esophageal irritation, dyspepsia, and abdominal pain are the most common reasons for discontinuation. Correct administration, swallowing with 240 mL of plain water, staying upright for 30 minutes, and taking the tablet at least 30 minutes before food, reduces but does not eliminate GI events [1]. Patients with Barrett's esophagus, active esophageal disease, or inability to sit upright for 30 minutes are generally excluded from bisphosphonate therapy per FDA prescribing information [1].

Osteonecrosis of the jaw (ONJ) occurs in fewer than 1 in 10,000 patients on oral bisphosphonates for osteoporosis, with risk increasing sharply in oncology doses [8]. Atypical subtrochanteric femur fracture is rare at approximately 3.2 to 50 per 100,000 patient-years and appears more common after more than 5 years of continuous use [9].

Romosozumab Tolerability

Injection-site reactions (pain, redness, bruising) occur in roughly 4% of patients and are usually mild [3]. The key safety concern is cardiovascular. In the ARCH trial, serious cardiovascular events (MI, stroke, cardiovascular death) occurred in 2.5% of the romosozumab group versus 1.9% in the alendronate group during the 12-month romosozumab treatment phase (P=0.07) [6]. The FDA responded with a boxed warning: romosozumab is contraindicated in patients who have had an MI or stroke within the preceding 12 months [3].

Hypocalcemia is a class-related risk. Baseline serum calcium and vitamin D should be adequate before starting therapy, and patients with severe renal impairment (eGFR <30 mL/min) are excluded from romosozumab treatment due to hypocalcemia risk [3].

Adherence Data Across Both Agents

Long-term adherence to weekly alendronate is poor. A large observational study found that fewer than 50% of patients remain adherent at 1 year, and non-adherence roughly doubles fracture risk [10]. Romosozumab's 12-month injectable course carries its own adherence burden but benefits from clinic-administered injections in many practices, which removes the daily or weekly patient-action requirement.

Switching From Fosamax to Evenity: Clinical Rationale and Sequencing

When a Switch Is Appropriate

Switching from alendronate to romosozumab may be considered when a patient on adequate bisphosphonate therapy continues to fracture, has declining BMD despite adherence, or carries a T-score below -3.5 with multiple risk factors. The AACE/ACE 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis state: "For patients at very high risk of fracture, particularly those with recent fractures, an anabolic agent is preferred as initial therapy or following an antiresorptive" [11].

The HealthRX clinical team uses a three-criteria framework to evaluate candidacy for a switch from alendronate to romosozumab:

1. Incident fracture on therapy after at least 12 months of documented alendronate adherence.
2. T-score below -2.5 at spine or hip after 3 or more years of antiresorptive therapy.
3. No MI, stroke, or high-risk cardiovascular event within the prior 12 months.

All three criteria should be present, or the first criterion alone with a recent fracture (within 24 months) qualifies a patient for escalation discussion.

What Happens to Prior Bisphosphonate Loading

Bisphosphonates bind to bone mineral and have a skeletal half-life of 10 years or more [12]. Residual alendronate in bone continues to suppress resorption even after stopping oral therapy. This residual effect does not blunt romosozumab's anabolic action, the ARCH trial enrolled women who had taken alendronate and showed strong BMD response to romosozumab regardless [6]. Prior bisphosphonate use does not contraindicate romosozumab.

Reversing the Switch: Going Back to Alendronate

Patients who complete 12 months of romosozumab must transition to an antiresorptive agent. Alendronate is a common choice. In the ARCH trial's extension phase, continuing alendronate after romosozumab maintained BMD gains and sustained fracture risk reduction through 24 months of total follow-up [6]. Stopping antiresorptive therapy after romosozumab results in rapid BMD loss, potentially back to or below baseline within 12 to 24 months [13].

Cost, Access, and Practical Considerations

Generic alendronate costs approximately $10 to $20 per month at most US pharmacies and is covered by nearly all insurance formularies with no prior authorization. Romosozumab costs approximately $1,800 to $2,000 per monthly injection before insurance, and payers consistently require documentation of prior bisphosphonate failure, a T-score below -2.5, or a recent fragility fracture before approving it [14].

Administration requirements also differ practically. Alendronate requires strict fasting and positional adherence on dosing days [1]. Romosozumab requires a trained provider or patient for subcutaneous injection and baseline laboratory work including serum calcium, phosphorus, and 25-OH vitamin D before initiation [3].

Patients with swallowing difficulties, severe GERD, or those who are unable to remain upright for 30 minutes after dosing are better candidates for injectable therapy. Patients with recent cardiovascular events, by contrast, must avoid romosozumab entirely.

Cardiovascular Risk: What Patients and Clinicians Need to Know

The cardiovascular signal in the ARCH trial was the single most consequential finding differentiating these two agents. The imbalance, 2.5% vs 1.9%, did not reach statistical significance at P=0.07, but the FDA judged the absolute risk increase sufficient to mandate a boxed warning [3]. A subsequent meta-analysis of romosozumab trials in the Journal of the American Heart Association found an odds ratio of 1.87 (95% CI 1.07 to 3.28) for cardiovascular events with romosozumab compared to active comparators [15].

Clinicians should screen all romosozumab candidates with a detailed cardiovascular history, review for recent statin or antiplatelet therapy needs, and reassess after the 12-month course before continuing any cardiovascular-active medication adjustments.

Guideline Positioning: Where Each Drug Sits

The Endocrine Society's 2019 Clinical Practice Guideline on Pharmacological Management of Osteoporosis recommends that postmenopausal women at very high fracture risk receive anabolic therapy before antiresorptive therapy to maximize skeletal benefit [16]. This positions romosozumab (or teriparatide/abaloparatide) above alendronate as first-line for the very high-risk category. Alendronate remains first-line for high-risk patients without the very high-risk designation, given its efficacy, cost, and safety profile over decades of use [16].

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) similarly recommends pharmacologic treatment for postmenopausal women with T-scores at or below -2.5, prior fragility fracture, or 10-year FRAX hip fracture probability at or above 3% or major osteoporotic fracture probability at or above 20% [17].

Monitoring Protocols for Each Agent

Monitoring on Alendronate

BMD by DXA should be repeated at 1 to 2 years after initiating alendronate and every 2 years thereafter [11]. Serum bone turnover markers, particularly CTX (C-terminal telopeptide), can confirm biochemical response within 3 to 6 months [18]. A CTX reduction of 25 to 50% from baseline after 3 months on alendronate suggests adequate adherence and GI absorption [18]. Renal function (serum creatinine) should be checked before initiation and periodically, given that bisphosphonates are renally cleared [1].

Monitoring on Romosozumab

Baseline calcium, phosphorus, and 25-OH vitamin D are required before the first injection [3]. Serum calcium should be rechecked at 1 month in patients at higher risk for hypocalcemia. Bone formation markers (P1NP) rise sharply within the first 1 to 3 months on romosozumab and then return toward baseline by month 9 to 12 as the anabolic window closes [19]. A DXA scan at the end of the 12-month course documents the achieved BMD gain and establishes a new baseline for antiresorptive therapy monitoring. Blood pressure and cardiovascular symptom review should accompany each monthly injection visit.

Patient Selection Summary

Neither drug is universally superior. The decision rests on individual patient factors.

Alendronate is the better starting point when cost is a constraint, when cardiovascular risk is elevated or recent, when the patient has no prior fractures on therapy, or when the fracture risk profile is high rather than very high. It is also appropriate as the sequential antiresorptive after completing romosozumab.

Romosozumab is preferred when a recent fracture has occurred (within the past 24 months), when T-score is below -3.0 with additional risk factors, when prior antiresorptive therapy has failed to prevent further bone loss, and when cardiovascular history is clear of MI or stroke in the preceding 12 months. Its 12-month treatment window and the mandatory transition to antiresorptive therapy afterward require careful upfront planning with the patient.